Heparin, low-molecular-weight heparins, and heparin pentasaccharide: Basic and clinical differentiationHOPPENSTEADT, Debra; WALENGA, Jeanine M; FAREED, Jawed et al.Hematology/oncology clinics of North America. 2003, Vol 17, Num 1, issn 0889-8588, ix, 313-341 [30 p.]Article

Les héparines = HeparinsLa Revue du praticien (Paris). 1988, Vol 38, Num 15, pp 917-964, issn 0035-2640, 44 p.Article

Interaction of oligopeptides with heparinRUIFENG ZHAO; HARATAKE, Mamoru; OTTENBRITE, Raphael M et al.Die Makromolekulare Chemie. Macromolecular symposia. 2001, pp 117-126, issn 0258-0322, isbn 3-527-30337-5Conference Paper

Conformation of the pentasaccharide corresponding to the binding site of heparin to antithrombin-IIIRAGAZZI, M; FERRO, D. R; PERLY, B et al.Carbohydrate research. 1987, Vol 165, Num 1, pp C1-C5, issn 0008-6215Article

The heparin story. In search of the early history of heparinBOTTIGER, L. E.Acta medica Scandinavica. 1987, Vol 222, Num 3, pp 195-200, issn 0001-6101Article

Thrombocytopenia associated with low-molecular-weight heparinLECOMPTE, T; SHAO KAI LUO; BERTRAND, J. C et al.Lancet (British edition). 1991, Vol 338, Num 8776, issn 0140-6736, p. 1217Article

Comparison of the antiangiogenic effects of heparin sodium, enoxaparin sodium, and tinzaparin sodium by using chorioallantoic membrane assayKATRANCIOGLU, Nurkay; KARAHAN, Oguz; TURHAN KILIC, Ahmet et al.Blood coagulation & fibrinolysis. 2012, Vol 23, Num 3, pp 218-221, issn 0957-5235, 4 p.Article

Sustained antithrombotic activity of hirudin after its plasma clearance : camparison with heparinAGNELLI, G; RENGA, C; WEITZ, J. I et al.Blood. 1992, Vol 80, Num 4, pp 960-965, issn 0006-4971Article

Heparin in angiography: current patterns of useMILLER, D. L.Radiology. 1989, Vol 172, Num 3, pp 1007-1011, issn 0033-8419, 5 p.Article

The pharmacodynamics of tinzaparin in healthy volunteersCAMBUS, Jean-Pierre; SAIVIN, Sylvie; HEILMANN, Jean-Jacques et al.British journal of haematology. 2002, Vol 116, Num 3, pp 649-652, issn 0007-1048Article

Molecular Weight measurements of low Molecular Weight heparins by gel permeation chromatographyMULLOY, B; GEE, C; WHEELER, S. F et al.Thrombosis and haemostasis. 1997, Vol 77, Num 4, pp 668-674, issn 0340-6245Article

Thrombin-induced platelet activation is inhibited by high- and low-molecular-weight heparinDE CANDIA, E; DE CRISTOFARO, R; LANDOLFI, R et al.Circulation (New York, N.Y.). 1999, Vol 99, Num 25, pp 3308-3314, issn 0009-7322Article

Antithrombin III- and heparin cofactor II-mediated anticoagulant and antiprotease actions of heparin and its synthetic analoguesJESKE, W; JAWED FAREED.Seminars in thrombosis and hemostasis. 1993, Vol 19, pp 241-247, issn 0094-6176, SUP1Article

Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulationZMUDA, K; NEOFOTISTOS, D; TS'AO, C.-H et al.American journal of clinical pathology. 2000, Vol 113, Num 5, pp 725-731, issn 0002-9173Article

Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitorALTMAN, R; SCAZZIOTA, A; ROUVIER, J et al.Haemostasis. 1998, Vol 28, Num 5, pp 229-235, issn 0301-0147Article

Structural features of heparin and their effect on heparin cofactor II mediated inhibition of thrombinKIM, Y. S; LINHARDT, R. J.Thrombosis research. 1989, Vol 53, Num 1, pp 55-71, issn 0049-3848Article

High and low molecular weight heparins do not modify red blood cell aggregability in vitroMARTINEZ, Marcial; VAYA, Amparo; LOPEZ-CAMACHO, Carolina et al.Clinical hemorheology and microcirculation. 2000, Vol 23, Num 1, pp 67-70, issn 1386-0291Article

Past, present and future considerations on low molecular weight heparin differentiation : An epilogueFAREED, J; HAAS, S; SASAHAR, A et al.Seminars in thrombosis and hemostasis. 1999, Vol 25, pp 145-147, issn 0094-6176, SUP3Conference Paper

Les héparines de bas poids moléculaire au Centre hospitalier général de Lons-le-Saunier : enquête sur les pratiques de prescription = Low-molecular-weight heparin prescription habits in Lons-le-Saunier hospitalLE BOUFFOS, C; BREANT, V; BILLION-REY, F et al.Journal de pharmacie clinique (Paris). 1999, Vol 18, Num OCT, pp 38-41, issn 0291-1981, NSConference Paper

Heparin - A Century of ProgressLEVER, Rebecca; MULLOY, Barbara; PAGE, Clive P et al.Handbook of experimental pharmacology. 2012, Vol 207, issn 0171-2004, 469 p.Serial Issue

Low-affinity heparin stimulates the inactivation of plasminogen activator inhibitor-1 by thrombinPATSTON, P. A; SCHAPIRA, M.Blood. 1994, Vol 84, Num 4, pp 1164-1172, issn 0006-4971Article

Pharmacologic properties of an unfractionated heparin butyryl derivative with long-lasting effectsSAIVIN, S; PETITOU, M; LORMEAU, J. C et al.The Journal of laboratory and clinical medicine. 1992, Vol 119, Num 2, pp 189-196, issn 0022-2143Article

Relevance of laboratory parameters to the clinical efficacy of FraxiparinHOPPENSTEADT, D; WALENGA, J. M; FAREED, J et al.Thrombotic and haemorrhagic disorders. 1991, Vol 4, Num 1, pp 7-12, issn 0934-9669Article

Kinetic analysis of the clotting system in the presence of heparin and depolarized heparinHEUCK, C.-C; BAUMANN, P.Haemostasis. 1991, Vol 21, Num 1, pp 10-18, issn 0301-0147Article

Clinical effect of low molecular wight heparin (Fragmin) on DIC : a multicenter cooperative study in JapanOGUMA, Y; SAKURAGAWA, N; MAKI, M et al.Thrombosis research. 1990, Vol 59, Num 1, pp 37-49, issn 0049-3848, 13 p.Article